Survey: The Top 5 Innovations and New Operational Strategies in Pharmaceutical R&D

According to a recent survey conducted by PPD, part of Thermo Fisher Scientific, 98% of drug developers report that, in the wake of COVID-19, they have embraced a wealth of new strategies across the entire clinical trial lifecycle – from adaptive trial design to big data. Find out how to apply these trends to your innovative clinical programs.

Oct. 17, 2022

BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

What these life science organizations’ latest executive-level appointments mean for the industry.

By Karissa Waddick • Oct. 14, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

By Kelly Bilodeau • Oct. 13, 2022

Robotic pills could open a world of possibilities for the biologics market

As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

By Karissa Waddick • Oct. 13, 2022

Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022

Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

By Alexandra Pecci • Oct. 11, 2022

New partnership may give MDMA an edge in the psychedelics space

While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

By Kelly Bilodeau • Oct. 10, 2022

The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

By Michael Gibney • Oct. 10, 2022

Woman of the Week: Janssen’s Fiona Elwood

The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

By Taren Grom • Oct. 5, 2022

To stay on the leading edge of oncology, AbbVie knows it has to take risks

In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

By Kelly Bilodeau • Oct. 4, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

By Michael Gibney • Oct. 3, 2022

Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

By PharmaVoice staff • Oct. 3, 2022

How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

By Michael Gibney • Sept. 30, 2022

Woman of the Week: Pepper Bio’s Samantha Dale Strasser

The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

By Taren Grom • Sept. 28, 2022

Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

Clinical registry data, a valuable source of real-world data

Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.

By CorEvitas • Sept. 6, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Woman of the Week: Thread’s Kim Boericke

Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

By Taren Grom • Aug. 31, 2022